3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
192
Lymphoma
102
Lymphoma, Non-Hodgkin
90
Leukemia, Myeloid, Acute
89
Precursor Cell Lymphoblastic Leukemia-Lymphoma
81
Myelodysplastic Syndromes
81
Hodgkin Disease
67
Leukemia
66
Neoplasms, Plasma Cell
65
Lymphoma, Large B-Cell, Diffuse
59
Leukemia, Lymphocytic, Chronic, B-Cell
58
Lymphoma, Mantle-Cell
52
Lymphoma, Follicular
49
Burkitt Lymphoma
39
Lymphoma, Large-Cell, Immunoblastic
35
Lymphoma, B-Cell, Marginal Zone
34
Myeloproliferative Disorders
30
Recurrence
28
Hematologic Neoplasms
28
Neuroblastoma
25
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
25
Leukemia, Myeloid, Accelerated Phase
24
Graft vs Host Disease
23
Leukemia, Myelomonocytic, Chronic
22
Leukemia, Myeloid, Chronic-Phase
22
Congenital Abnormalities
21
Immunoglobulin Light-chain Amyloidosis
20
Dendritic Cell Sarcoma, Interdigitating
19
Primary Myelofibrosis
18
Waldenstrom Macroglobulinemia
17
Interventions
pembrolizumab
2
fludarabine
2
Radiosurgery
2
Paclitaxel
2
Gemcitabine
2
Cyclophosphamide
2
Cisplatin
2
Carboplatin
2
Anthropogenic Effects
2
venetoclax
1
umbralisib
1
ublituximab
1
regorafenib
1
pazopanib
1
niraparib
1
neratinib
1
lutetium Lu 177 dotatate
1
ibrutinib
1
grapiprant
1
fludarabine phosphate
1
famitinib
1
encorafenib
1
copanlisib
1
cemiplimab
1
capivasertib
1
camrelizumab
1
brigatinib
1
binimetinib
1
axicabtagene ciloleucel
1
avelumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Disease Progression
×
Melphalan
×
Clear all
NCT02043847
2024-11-13
BMT-03
University of Illinois at Chicago
Phase 1
Completed
12 enrolled
12 charts